CMS4-focused multi-omic integration enhances antigen target identification in colorectal cancer

Colorectal cancer (CRC) remains a major cause of cancer mortality, with limited options for poor-prognosis subtypes such as CMS4. Antigen-targeted therapies show promise but tend to fail due to inadequate target selection and insufficient patient stratification. Effective prioritization requires large harmonized data capturing CRC heterogeneity - a resource that is currently lacking. To address this need, we built a harmonized multi-omic CRC knowledge base and applied a scalable discovery pipeline to identify antigen targets specifically associated with CMS4 biology and with strong translational potential. We constructed a harmonized CRC atlas by integrating 79 transcriptomics datasets (5,033 tumors, 161 normal samples) using proprietary AI-powered data scouting, integration, and curation technologies. Consensus Molecular Subtypes (CMS) were inferred to capture CMS4-specific expression patterns and this atlas was then combined with 3 bulk RNA-seq reference datasets, 2 single-cell atlases, and 8 protein annotation databases to form a unified multi-omic CRC knowledge base of unmatched scale. From this integrated system, we identified genes differentially expressed in CMS4 patients encoding druggable cell-surface proteins, which we then prioritized using a weighted efficacy- and safety-based scoring model. We identified 236 CMS4-enriched candidates, including 124 not detectable at the CRC-wide level, demonstrating the added resolution gained through subtype stratification. Recovery of known investigational CRC (LGR5, MET, TACSTD2) and CMS4-associated targets of clinical emerging interest (PDGFRB, ALK5/TGFBR1, FAP) support the biological and methodological validity of our approach. Benchmarking against thresholds from FDA-approved pan-cancer targets and terminated trials identified 32 candidates with comparable or superior therapeutic profiles. Among these, 11 were enriched for CMS4-defining pathways, including epithelial-mesenchymal transition, angiogenesis, and stromal invasion, and 5 showed strong profile similarity to established CRC and CMS4 benchmarks. After extensive data exploration, particularly promising candidates were shortlisted for further validation. This work shows that CMS4-focused molecular stratification, when combined with an unprecedentedly large harmonized multi-omic knowledge base, yields a refined set of antigen candidates with enhanced specificity, safety, and biological relevance. The prioritized targets illustrate the power of subtype-resolved discovery to uncover clinically actionable insights. Our pipelines modular design can extend to other tumor contexts, offering a robust foundation for accelerating targeted therapy development.